Beyond Traditional Monoclonal Antibodies

Novel antibody formats are being developed to improve clinical results by providing a wider range of biological effects. While this innovation offers enormous therapeutic potential, it also presents new purification challenges for drug manufacturers. Unlike traditional monoclonal antibodies, these new molecules are created using complex synthesis techniques that lead to equally novel impurity profiles, including undesired by-products and high or low molecular weight species.

These impurities can not only reduce the overall yield but also increase the risk of immune reactions, making their removal during the purification process crucial for maintaining a safe drug product. To overcome these challenges, new approaches are being developed, including modifying existing chromatography methods and creating specialized media that can effectively separate impurities during the capture step.

Read the full white paper to learn more about the purification challenges posed by new antibody formats and how innovative affinity resins can help address them.